SERB Pharmaceuticals to buy European & MENA rights of Idefirix from Hansa Biopharma for €115 million: Brussels Thursday, May 21, 2026, 11:00 Hrs [IST] SERB Pharmaceuticals, a fa ...

SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) today announced that they have entered into an agreement under which SERB will acquire the exclusive development ...

Middle East and North Africa (MENA) states remain in the thic of things as experts claim captagon trafficking could change ...

SERB Pharmaceuticals and Hansa Biopharma AB (HNSA.ST) announced Tuesday their agreement, under which SERB will acquire exclusive ...

Hansa will receive €110m upfront and a further €5m once the European Medicines Agency accepts Idefirix’s full approval filing.

May 19 (Reuters) - Hansa Biopharma said on Tuesday it had agreed to license its kidney transplant drug Idefirix to privately held SERB Pharmaceuticals in Europe and some other markets for up to 115 ...

A drug-sniffing dog flagged an eastbound semi on I-10, leading deputies to 9 kilos of cocaine stuffed inside the cab walls.

Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ STOCKHOLM: HNSA) and SERB S.A. ("SERB") today announced an exclusive licensing ...

Collaborations structured across three strategic clusters, supporting Globalpharma’s efforts to strengthen capabilities ...

Operation RAGEPILL is the multi-agency NCB initiative that targeted an international smuggling consignment bound for the ...

Also highlighting China's squid fishing fleet off Argentina, how redistricting is shaping America's midterms, and why 2.1 ...

Women’s health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026.